Photo from academic.microsoft.com
Dexpramipexole, a drug recently tested in patients with amyotrophic lateral sclerosis (ALS,) is able to bind F1Fo ATP synthase and increase mitochondrial ATP production. Here, we have investigated its effects… Click to show full abstract
Dexpramipexole, a drug recently tested in patients with amyotrophic lateral sclerosis (ALS,) is able to bind F1Fo ATP synthase and increase mitochondrial ATP production. Here, we have investigated its effects on experimental ischaemic brain injury.
Keywords:
outcome experimental;
experimental stroke;
pharmacology;
dexpramipexole improves;
bioenergetics outcome;
improves bioenergetics
Journal Title: British Journal of Pharmacology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: British Journal of Pharmacology
Year Published: 2018
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!